TScan Therapeutics, Inc.TCRXNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank4
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P4
Near historical low
vs 5Y Ago
-0.3x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-17.04%
Q3 2025-13.69%
Q2 20255.46%
Q1 202515.93%
Q4 2024-1.54%
Q3 2024-2.38%
Q2 20249.97%
Q1 202441.38%
Q4 2023-17.17%
Q3 2023-9.75%
Q2 2023-15.91%
Q1 202366.82%
Q4 2022-5.17%
Q3 20222.12%
Q2 20226.99%
Q1 20221.03%
Q4 20219.88%
Q3 202148.50%
Q2 20214.60%
Q1 2021-1.33%
Q4 202060.25%
Q3 202047.94%
Q2 2020-16.74%
Q1 20200.00%
Q4 20190.00%